Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2018
Reporting Period: Quarterly period ended June 30, 2018
Status: Emerging Growth Company
This filing serves as a notification that the company issued a press release on August 8, 2018, announcing its financial results for the quarter ended June 30, 2018. The full text of the press release is included as Exhibit 99.1.
Key Financial Metrics
The provided filing text acts as a cover document and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached press release (Exhibit 99.1), which is not included in the input text.
Note: The filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this Form 8-K. The document solely references the issuance of the quarterly results announcement.
Guidance, Outlook, and Risks
The filing text does not provide specific details on guidance, outlook, management commentary, risks, contingencies, or unusual items. These elements are presumed to be discussed in the attached press release (Exhibit 99.1).
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 8, 2018) for actual revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm if the company has elected to use the extended transition period for new accounting standards (indicated as "yes" in the filing).